Business
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional
About this update from Zymeworks Inc.
[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nZymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 taking place virtually from April 10 – 15, 2021.\n\nThe poster presentations will be available on Saturday, April 10 at 8:30 am ET on the conference website as well as the Zymeworks website.\n\nPresentation Details\n\nTitle: PROTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics\nAbstract: 924\nSession Category: Experimental and Molecular Therapeutics\nSession Title: Antibody Technologies\n\nTitle: Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation\nAbstract: 1788\nSession Category: Immunology\nSession Title: Modifiers of the Tumor Microenvironment\n\nTitle: Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB\nAbstract: 1737\nSession Category: Immunology\nSession Title: Immunomodulatory Agents and Interventions\n\nTitle: Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action\nAbstract: 1032\nSession Category: Experimental and Molecular Therapeutics\nSession Title: Cellular Responses to Anticancer Drugs\n\nTitle: The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers\nAbstract: 1005\nSession Category: Experimental and Molecular Therapeutics\nSession Title: Cellular Responses to Anticancer Drugs\n\nAbout Zymeworks Inc. \n\nZymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract...